The weight-loss drug market has ballooned to $80 billion. And the two pharmaceutical companies currently duking it out for market dominance, Novo Nordisk and Eli Lilly, have a century-long rivalry.
Bloomberg News health reporter Madison Muller breaks down how Eli Lilly developed Zepbound, a new drug that can help patients cut more than 20% of their body weight — and why some investors and analysts think it will turn Eli Lilly into the first ever trillion-dollar drug company.See omnystudio.com/listener for privacy information.